Mewburn Ellis LLP

Address:
33 Gutter Lane
London
EC2V 8AS

Contact:
Stephen Carter, Partner, European Patent Attorney

Telephone:
+44 (0)20 7776 5300

Email:
mail@mewburn.com

Website:
www.mewburn.com

MEWBURN ELLIS LLP is one of the UK’s largest firms of European Patent, Trade Mark and Design Attorneys, with offices in London, Bristol, Manchester and Cambridge. Our work covers a wide range of technologies and a significant amount of our work comes from clients in the UK, both large and small.

We have a forward-thinking and relatively young partnership. Many of our attorneys have taken the opportunity while training to work in overseas law firms to gain wider experience of global IP issues. We pride ourselves on being both pro-active and responsive to clients’ needs and requests and on our clear straightforward, creative, practical advice to our clients. We have a transparent and flexible billing system and competitive billing rates.

We work closely with our clients to file and prosecute patent, trade mark and design applications in the UK and across Europe, and to manage portfolios of applications around the world. We also handle contentious matters, including oppositions at the UKIPO, the EPO and OHIM, the office that administers EU trade marks. Our care of our clients’ intellectual property portfolios does not stop at prosecuting applications or enforcement.

In addition to obtaining European patents for our clients we undertake a considerable amount of “IP due diligence” work of all types, and scopes, including IPO, trade-sale, M&A, inward investment and licensing.

Since 1991 we have included in our practice a team of qualified lawyers. This team provides us with increased expertise in applying for, maintaining and enforcing intellectual property rights, and to assist our clients in exploiting those rights.

We regularly advise clients on a wide range of legal matters including:


We do not carry out instructions passively, but seek actively to make additional contributions using our special expertise. This distinctive approach often leads to beneficial changes in a proposed course of action, especially as we treat our clients’ intellectual property rights not in isolation, but as part of their legal, commercial and industrial environment.

MEWBURN ELLIS LLP has a highly experienced team of Life Sciences specialists. Our Life Sciences team are highly regarded for their superior knowledge and expertise in this often contentious area of patent law.

Attorneys in our medical devices team are drawn from a broad range of technical backgrounds, including engineering, electronics, materials science, biotechnology and chemistry, enabling us to bring experience appropriate to our clients’ technology to each case we handle. Areas of the medical device field in which we have particular experience include stents; materials such as dental, ophthalmic and orthopaedic materials; ophthalmic devices including retinal implants and ophthalmic lenses; nebulisers and drug delivery systems; wound healing systems; tissue culture systems and tissue scaffold materials; implantable sensors and other diagnostic instruments; surgical instruments; catheters and syringes.

We also have one of the largest and most respected groups of patent attorneys specialising in biotechnology in Europe, with specialised sub-groups and cross-disciplinary groups in areas such as industrial and agricultural biotechnology, plant sciences, pharmaceutical biotechnology, nanotechnology, analytical techniques, diagnostics, clean tech, and regenerative medicine.

Our experienced team of life sciences experts has grown organically with our many clients. An increasing proportion of our direct work is for small or medium sizes life sciences companies in and around Europe. Additionally, we represent directly or indirectly more than 30 Universities or their corresponding technology transfer offices.

Do get in touch with MEWBURN ELLIS LLP if you’d like more information on any of the matters discussed above or if you would like to speak to someone regarding your IP strategy.
Related Mewburn Ellis LLP news stories
UK Bolar broadening to attract clinical trials - 03 October 2014
UK firm hires associates in Leeds and London - 02 May 2014
AstraZeneca acquires Spirogen in $440 million deal - 18 October 2013
Quest rivals Myriad with BRCA gene test - 17 October 2013


Related Mewburn Ellis LLP features
What’s in a name? - 14 November 2013
Map out a path through the IP maze - 03 October 2013


Related Mewburn Ellis LLP interviews
Robert Andrews - 31 October 2013
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization